115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers
    Meeting Abstract

    Hamilton, E. P.; Chaudhry, A.; Spira, A. I.; Adams, S.; Abuhadra, N.; Giordano, A.; Parajuli, R.; Han, H. S.; Weise, A. M.; Marchesani, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors
    Meeting Abstract

    Bodei, L.; Kavan, P.; Liberman, M.; Taunk, N.; Metser, U.; Juneau, D.; O'Reilly, E. M.; Ma, J.; Cioci, R.; Abdul Razak, A. R.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 trial of a novel C'Dot drug conjugate (CDC), ELU001, in patients with solid tumors known to overexpress folate receptor alpha (FRα)
    Meeting Abstract

    Ma, W. W.; Tolcher, A. W.; Perez, C. A.; Orr, D.; Hamilton, E. P.; Zhao, Y.; Murciano-Goroff, Y. R.; Anders, C. K.; Adams, G. P.; Reddick, C. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 trial of GD2-SADA: (177)Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma
    Meeting Abstract

    Owonikoko, T. K.; Moser, J. C.; Yoon, J.; Slotkin, E. K.; Dowlati, A.; Ma, V. T.; Düring, M.; Sveistrup, J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE)
    Meeting Abstract

    Torres, A.; Aaron, M.; White, L.; D'Andrea, K.; Narayan, V.; Knollman, H. M.; Bradbury, A. R.; Tung, N. M.; Robson, M. E.; Nathanson, K.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC)
    Meeting Abstract

    Mayer, E. L.; Tolaney, S. M.; Brufsky, A.; Gradishar, W. J.; Jhaveri, K. L.; Martin, M.; Moscetti, L.; Schneeweiss, A.; Vidal, G. A.; Cortazar, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase I/II study of stereotactic radiosurgery with concurrent olaparib followed by adjuvant durvalumab and physician's choice systemic therapy in patients with breast cancer brain metastases
    Meeting Abstract

    Shen, C.; Abdou, Y.; Chen, L.; Tan, X.; Gupta, G. P.; Lynce, F.; Lobbous, M.; Stringer-Reasor, E. M.; Anders, C. K.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer
    Meeting Abstract

    McArthur, H. L.; Comen, E. A.; Bryce, Y.; Solomon, S. B.; Leal, J. H. S.; Abaya, C. D.; Martinez, C.; Basho, R. K.; McAndrew, P.; Larkin, B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The ARETHA study: A phase 2 randomized control trial of eribulin with evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer (TNBC) and metabolic dysfunction
    Meeting Abstract

    Shen, S.; Solomon, V.; Williams, D.; Robson, M. E.; Norton, L.; Traina, T. A.; Iyengar, N. M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma
    Meeting Abstract

    Schaff, L.; Fortunato, J.; Grommes, C.; Gavrilovic, I. T.; Lin, A.; Pentsova, E.; Miller, A.; Newton, A.; Gonzalez, A.; Mellinghoff, I. K.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save